Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1173110

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1173110

Asia Pacific Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type, By Route of Administration, By Treatment Type, By Drug Type, By Country and Growth Forecast, 2022 - 2028

PUBLISHED:
PAGES: 99 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Site License)
USD 1800
PDF (Enterprisewide License)
USD 2520

Add to Cart

The Asia Pacific Spinal Muscular Atrophy Treatment Market would witness market growth of 19.4% CAGR during the forecast period (2022-2028).

Survival motor neuron gene 2 (SMN2), often known as the SMA backup gene, is a second gene that is present in all people with SMA in at least one and frequently numerous copies. Although SMN2 also creates SMN protein, the body can only utilize a limited portion of this protein. Numerous therapies that increase the usability of SMN protein target the SMN2 gene. Other SMN-enhancing methods directly replace or correct the mutated SMN1 gene.

Considering motor neurons are the cells most severely impacted by SMA, neuroprotective measures directed at this group of neurons may be successful, especially when combined with SMN-restoring therapy. One of the main symptoms of SMA type 2/3 is repeated nerve conduction and increased fatigability investigations reveal a decline, indicating that neuromuscular junction (NMJ) dysfunction may be significantly contributing to fatigability.

Therefore, pyridostigmine, an acetylcholinesterase inhibitor commonly recommended for myasthenia gravis, is presently being studied in phase II clinical trials to determine its impact on the efficiency of cholinergic transmission. According to early observations, pyridostigmine decreases patient fatigability and therefore, is considered a potential supplementary therapy.

Several studies were conducted in this region to figure out the psychosocial impacts of SMA on patients, families, and caretakers. More than half of the participants reported experiencing stress, and the majority of the caregivers reported experiencing anxiety. This is consistent with earlier studies that reported the great emotional costs associated with living with SMA. This may be because getting psychological counseling is culturally stigmatized in Asia, where people are taught to keep their emotions to themselves.

The China market dominated the Asia Pacific Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $523.6 million by 2028. The Japan market is estimated to grow a CAGR of 18.6% during (2022 - 2028). Additionally, The India market would experience a CAGR of 20.1% during (2022 - 2028).

Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Scope of the Study

Market Segments covered in the Report:

By Type

  • Type 1
  • Type 2
  • Type 3
  • Type 4

By Route of Administration

  • Injection
  • Oral

By Treatment Type

  • Drug
    • Spinraza
    • Zolgensma (AVXS-101)
    • Evrysdi
    • Others
  • Gene Therapy

By Country

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled

  • Biogen, Inc.
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • PTC Therapeutics, Inc.
  • NMD Pharma A/S
  • Scholar Rock, Inc. (Scholar Rock Holding Corporation)
  • Cytokinetics, Inc.
  • Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
  • Astellas Pharma, Inc.
  • F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific Spinal Muscular Atrophy Market, by Type
    • 1.4.2 Asia Pacific Spinal Muscular Atrophy Market, by Route of Administration
    • 1.4.3 Asia Pacific Spinal Muscular Atrophy Market, by Treatment Type
    • 1.4.4 Asia Pacific Spinal Muscular Atrophy Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market

Chapter 4. Asia Pacific Spinal Muscular Atrophy Treatment Market by Type

  • 4.1 Asia Pacific Type 1 Market by Country
  • 4.2 Asia Pacific Type 2 Market by Country
  • 4.3 Asia Pacific Type 3 Market by Country
  • 4.4 Asia Pacific Type 4 Market by Country

Chapter 5. Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration

  • 5.1 Asia Pacific Injection Market by Country
  • 5.2 Asia Pacific Oral Market by Country

Chapter 6. Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type

  • 6.1 Asia Pacific Drug Market by Country
  • 6.2 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type
    • 6.2.1 Asia Pacific Spinraza Market by Country
    • 6.2.2 Asia Pacific Zolgensma (AVXS-101) Market by Country
    • 6.2.3 Asia Pacific Evrysdi Market by Country
    • 6.2.4 Asia Pacific Others Market by Country
  • 6.3 Asia Pacific Gene Therapy Market by Country

Chapter 7. Asia Pacific Spinal Muscular Atrophy Treatment Market by Country

  • 7.1 China Spinal Muscular Atrophy Treatment Market
    • 7.1.1 China Spinal Muscular Atrophy Treatment Market by Type
    • 7.1.2 China Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.1.3 China Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.1.3.1 China Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.2 Japan Spinal Muscular Atrophy Treatment Market
    • 7.2.1 Japan Spinal Muscular Atrophy Treatment Market by Type
    • 7.2.2 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.2.3 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.2.3.1 Japan Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.3 India Spinal Muscular Atrophy Treatment Market
    • 7.3.1 India Spinal Muscular Atrophy Treatment Market by Type
    • 7.3.2 India Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.3.3 India Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.3.3.1 India Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.4 South Korea Spinal Muscular Atrophy Treatment Market
    • 7.4.1 South Korea Spinal Muscular Atrophy Treatment Market by Type
    • 7.4.2 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.4.3 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.4.3.1 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.5 Australia Spinal Muscular Atrophy Treatment Market
    • 7.5.1 Australia Spinal Muscular Atrophy Treatment Market by Type
    • 7.5.2 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.5.3 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.5.3.1 Australia Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.6 Malaysia Spinal Muscular Atrophy Treatment Market
    • 7.6.1 Malaysia Spinal Muscular Atrophy Treatment Market by Type
    • 7.6.2 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.6.3 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.6.3.1 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type
  • 7.7 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
    • 7.7.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
    • 7.7.2 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
    • 7.7.3 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
      • 7.7.3.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type

Chapter 8. Company Profiles

  • 8.1 PTC Therapeutics, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Regional Analysis
    • 8.1.4 Research & Development Expenses
    • 8.1.5 Recent strategies and developments:
      • 8.1.5.1 Partnerships, Collaborations, and Agreements:
      • 8.1.5.2 Acquisition and Mergers:
      • 8.1.5.3 Approvals and Trials:
  • 8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Segmental and Regional Analysis
    • 8.2.4 Research & Development Expense
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Approvals and Trials:
      • 8.2.5.2 Acquisition and Mergers:
  • 8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Regional & Segmental Analysis
    • 8.3.4 Research & Development Expense
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Partnerships, Collaborations, and Agreements:
  • 8.4 Novartis AG
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Approvals and Trials:
      • 8.4.5.2 Acquisition and Mergers:
  • 8.5 Ionis Pharmaceuticals, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Research & Development Expenses
    • 8.5.4 Recent strategies and developments:
      • 8.5.4.1 Acquisition and Mergers:
  • 8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Research & Development Expenses
  • 8.7 Cytokinetics, Incorporated
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Research & Development Expenses
  • 8.8 Astellas Pharma, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional Analysis
    • 8.8.4 Research & Development Expense
  • 8.9 Biogen, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expense
  • 8.10. NMD Pharma A/S
    • 8.10.1 Company Overview
    • 8.10.2 Recent strategies and developments:
      • 8.10.2.1 Geographical Expansions:

LIST OF TABLES

  • TABLE 1 Asia Pacific Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 2 Asia Pacific Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 3 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Asia Pacific Type 1 Market by Country, 2018 - 2021, USD Million
  • TABLE 6 Asia Pacific Type 1 Market by Country, 2022 - 2028, USD Million
  • TABLE 7 Asia Pacific Type 2 Market by Country, 2018 - 2021, USD Million
  • TABLE 8 Asia Pacific Type 2 Market by Country, 2022 - 2028, USD Million
  • TABLE 9 Asia Pacific Type 3 Market by Country, 2018 - 2021, USD Million
  • TABLE 10 Asia Pacific Type 3 Market by Country, 2022 - 2028, USD Million
  • TABLE 11 Asia Pacific Type 4 Market by Country, 2018 - 2021, USD Million
  • TABLE 12 Asia Pacific Type 4 Market by Country, 2022 - 2028, USD Million
  • TABLE 13 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 14 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 15 Asia Pacific Injection Market by Country, 2018 - 2021, USD Million
  • TABLE 16 Asia Pacific Injection Market by Country, 2022 - 2028, USD Million
  • TABLE 17 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 18 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 19 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 20 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 21 Asia Pacific Drug Market by Country, 2018 - 2021, USD Million
  • TABLE 22 Asia Pacific Drug Market by Country, 2022 - 2028, USD Million
  • TABLE 23 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 24 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 25 Asia Pacific Spinraza Market by Country, 2018 - 2021, USD Million
  • TABLE 26 Asia Pacific Spinraza Market by Country, 2022 - 2028, USD Million
  • TABLE 27 Asia Pacific Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
  • TABLE 28 Asia Pacific Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
  • TABLE 29 Asia Pacific Evrysdi Market by Country, 2018 - 2021, USD Million
  • TABLE 30 Asia Pacific Evrysdi Market by Country, 2022 - 2028, USD Million
  • TABLE 31 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 32 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 33 Asia Pacific Gene Therapy Market by Country, 2018 - 2021, USD Million
  • TABLE 34 Asia Pacific Gene Therapy Market by Country, 2022 - 2028, USD Million
  • TABLE 35 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
  • TABLE 36 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
  • TABLE 37 China Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 38 China Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 39 China Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 40 China Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 41 China Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 42 China Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 43 China Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 44 China Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 45 China Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 46 China Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 47 Japan Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 48 Japan Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 49 Japan Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 50 Japan Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 51 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 52 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 53 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 54 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 55 Japan Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 56 Japan Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 57 India Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 58 India Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 59 India Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 60 India Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 61 India Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 62 India Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 63 India Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 64 India Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 65 India Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 66 India Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 67 South Korea Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 68 South Korea Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 69 South Korea Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 70 South Korea Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 71 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 72 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 73 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 74 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 75 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 76 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 77 Australia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 78 Australia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 79 Australia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 80 Australia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 81 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 82 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 83 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 84 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 85 Australia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 86 Australia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 87 Malaysia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 88 Malaysia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 89 Malaysia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 90 Malaysia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 91 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 92 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 93 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 94 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 95 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 96 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 97 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
  • TABLE 98 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
  • TABLE 99 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
  • TABLE 100 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
  • TABLE 101 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 102 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 103 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
  • TABLE 104 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
  • TABLE 105 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
  • TABLE 106 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
  • TABLE 107 Key Information - PTC Therapeutics, Inc.
  • TABLE 108 key information - F. Hoffmann-La Roche Ltd.
  • TABLE 109 Key Information - Biohaven Pharmaceutical Holding Company Ltd.
  • TABLE 110 Key Information - Novartis AG
  • TABLE 111 Key information - Ionis Pharmaceuticals, Inc.
  • TABLE 112 Key Information - Scholar Rock, Inc.
  • TABLE 113 Key Information - CYTOKINETICS, INCORPORATED
  • TABLE 114 key information - Astellas Pharma, Inc.
  • TABLE 115 Key Information - Biogen, Inc.
  • TABLE 116 Key Information - nmd pharma a/s

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Recent strategies and developments: PTC Therapeutics, Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!